Delivery Order SPE2DB20D1100-SPE2DB25FE3R6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,768.42 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pens. This firm fixed price contract, which is not set-aside and is scheduled for completion by July 28, 2025, represents a competitive award to the pharmaceutical distributor for medical supplies supporting federal healthcare operations. The delivery will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $3,050.40 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 4, 2025. The order will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order represents a...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $3,431.61 on August 21, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed-price, non-set-aside delivery order is scheduled for completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen's larger relationship...
- The Defense Logistics Agency awarded a $5,476.25 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 30, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to compete in open federal procurement processes for...
- The Defense Logistics Agency awarded a $5,630.51 delivery order to AmerisourceBergen Drug Corp on August 10, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. This firm fixed price contract, with an ultimate completion date of August 11, 2025, represents a small-value pharmaceutical procurement supporting federal medical supply needs. The award was made on a competitive basis without any set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $26.7K delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Zepbound 10 mg/0.5 mL pens with an ultimate completion date of September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's significant role as a pharmaceutical supplier to the federal government, leveraging...
- The Defense Logistics Agency awarded a $1,584.34 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens. This firm fixed-price, non-competitive delivery order is set to be completed by August 19, 2025, with performance occurring at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pens valued at $17,343.17 with a firm fixed price contract type. This order, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a competitive award with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a $2,465.15 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed price, non-set-aside contract represents a small-value pharmaceutical delivery to support federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for military and veteran healthcare systems through its extensive...
- The Defense Logistics Agency awarded a $9,018.43 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 25, 2025. The product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE3R6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. The contract, which is not set-aside and operates under firm fixed pricing, is scheduled for completion by September 2, 2025. AmerisourceBergen will perform this work from its corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and military healthcare systems. The company holds a significant presence in the DLA Medical Supply Chain through its prime IDC and has demonstrated capability to competitively meet federal procurement requirements across a broad range of pharmaceutical products, medical devices, and specialty healthcare commodities. This award reflects the company's ongoing role as a primary pharmaceutical supplier within the federal government's medical procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/29/25 |